Vaginal infection Trials in Disease

Study on the Effectiveness and Safety of BGY-1601-VT for Women with Acute Vaginal Infections, Including Bacterial Vaginosis and Yeast Infections

This clinical trial is testing a new treatment for women experiencing acute vaginal infections, including bacterial vaginosis (an imbalance of natural vaginal bacteria), vulvovaginal candidiasis (a yeast infection), or a combination of both conditions.

Inclusion criteria: Women eligible to participate must be between 18 and 50 years old and still having menstrual periods. They need to have symptoms suggesting a vaginal infection, such as unusual or heavy discharge, thick discharge, a fishy smell, or itching and burning in the vaginal area. Participants must not be at risk of becoming pregnant and must have a negative pregnancy test. They should be in good general and mental health with no significant medical issues, able to follow study procedures, and have health insurance coverage.

Exclusion criteria: The study cannot include men or women without a confirmed diagnosis of bacterial vaginosis, vulvovaginal candidiasis, or a mixed infection of both conditions. Individuals who are part of vulnerable populations and may not be able to provide informed consent are also excluded.

Focus and goal: The trial aims to compare the effectiveness and safety of BGY-1601-VT vaginal tablets with a placebo (an inactive treatment that looks identical). The study is double-blind, meaning neither participants nor researchers know who receives the active treatment until the study ends, which helps ensure unbiased results. Participants receive treatment for 7 to 10 days, with follow-up evaluations occurring 7 days after starting treatment. Researchers will monitor how well the treatment reduces symptoms such as discharge, itching, and burning, while also tracking any side effects to assess safety.

Investigational drug: The treatment being tested is BGY-1601-VT, a vaginal tablet containing live Lactobacillus rhamnosus bacteria (strain LCR35). This beneficial bacteria is designed to help restore the natural balance of the vaginal environment. The medication is classified as a live biotherapeutic product and is being evaluated as a potential first-line treatment for these common types of vaginal infections.